NO20045023L - Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer - Google Patents

Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer

Info

Publication number
NO20045023L
NO20045023L NO20045023A NO20045023A NO20045023L NO 20045023 L NO20045023 L NO 20045023L NO 20045023 A NO20045023 A NO 20045023A NO 20045023 A NO20045023 A NO 20045023A NO 20045023 L NO20045023 L NO 20045023L
Authority
NO
Norway
Prior art keywords
crystals
steroids
pharmaceutical formulations
preparation
particle size
Prior art date
Application number
NO20045023A
Other languages
English (en)
Inventor
Detlef Grawe
Peter Hosel
Uwe Mueller
Annette Eichardt
Hagen Gerecke
Sabine Gliesing
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20045023L publication Critical patent/NO20045023L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0085—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det er beskrevet en fremgangsmåte for fremstilling av krystaller av steroider hvis gjennomsnittlige partikkelstørrelse Ugger i et på forhånd gitt orm-åde og hvis maksimale partikkelstørrelse ikke overskrider en på forhånd gitt verdi, hvorved en overmettet oppløsning av steroidene under krystalhsasjonen underkastes en våtmaling ved hjelp av en irmretning for våtmaling, hvorved en primærkomsuspensjon oppnås. Det er videre beskrevet ved derme fremgangsmåten oppnåelige krystaller samt farmasøytiske formuleringer irmeholdende disse.
NO20045023A 2002-04-23 2004-11-18 Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer NO20045023L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10218107A DE10218107A1 (de) 2002-04-23 2002-04-23 Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
PCT/EP2003/004154 WO2003091272A1 (de) 2002-04-23 2003-04-22 Verfahren zum herstellen von kristallen von steroiden, danach erhältliche kristalle und deren verwendung in pharmazeutischen formulierungen

Publications (1)

Publication Number Publication Date
NO20045023L true NO20045023L (no) 2004-11-18

Family

ID=29264787

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045023A NO20045023L (no) 2002-04-23 2004-11-18 Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer

Country Status (20)

Country Link
US (1) US7148212B2 (no)
EP (1) EP1497308B1 (no)
JP (1) JP4490116B2 (no)
KR (1) KR20040106380A (no)
CN (1) CN1646555A (no)
AT (1) ATE340186T1 (no)
AU (1) AU2003232491A1 (no)
BR (1) BR0309357A (no)
CA (1) CA2480004C (no)
DE (2) DE10218107A1 (no)
DK (1) DK1497308T3 (no)
ES (1) ES2274258T3 (no)
IL (1) IL163986A0 (no)
MX (1) MXPA04010467A (no)
NO (1) NO20045023L (no)
PL (1) PL371340A1 (no)
PT (1) PT1497308E (no)
RU (1) RU2315056C2 (no)
WO (1) WO2003091272A1 (no)
ZA (1) ZA200409401B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
ES2327665T3 (es) * 2006-08-10 2009-11-02 JENAPHARM GMBH & CO. KG Forma medicamentosa peroral con dienogest y etinilestradiol para la contracepcion.
US20080038350A1 (en) * 2006-08-10 2008-02-14 Hagen Gerecke Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
DE102010003711B4 (de) 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
RU2642244C2 (ru) * 2010-04-12 2018-01-24 Кларус Терапеутикс, Инк. Оральные фармацевтические композиции сложных эфиров тестостерона и способы лечения недостатка тестостерона с их использованием
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
EP3143001B1 (en) 2014-05-13 2018-07-18 Akzo Nobel Chemicals International B.V. Process to crystallize chelating agents
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
JP2021531348A (ja) 2018-07-20 2021-11-18 リポシン，インク． 肝臓病
US12570627B2 (en) 2020-05-15 2026-03-10 Shionogi & Co., Ltd. Pharmaceutical composition in which production of impurities is suppressed

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226389A (en) 1962-01-04 1965-12-28 Du Pont 11,11,12,12-tetracyano-naphtho-2,6-quinodimethan and its anion-radical salts
KR0132576B1 (ko) 1988-10-05 1998-04-17 로렌스 티. 웰츠 항-용매 내로의 침전을 통한 미분 고형물 결정 분말의 제조 방법
DE3917617A1 (de) 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
FR2668945B1 (fr) 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
ES2126977T3 (es) 1991-07-10 1999-04-01 Chiyoda Chem Eng Construct Co Procedimento para la produccion de aducto cristalino de bisfenol a y fenol.
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1995018018A1 (en) * 1993-12-27 1995-07-06 Nippon Soda Co. Ltd. 4-hydroxy-4'-isopropoxydiphenyl sulfone developer composition, wet pulverizing method, and dispersion
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
CN1183102C (zh) * 1998-12-25 2005-01-05 第一精密化学株式会社 泛酸钙的制备方法
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Also Published As

Publication number Publication date
DE10218107A1 (de) 2003-11-20
IL163986A0 (en) 2005-12-18
RU2004134324A (ru) 2006-02-10
PL371340A1 (en) 2005-06-13
CN1646555A (zh) 2005-07-27
MXPA04010467A (es) 2004-12-13
JP2005524698A (ja) 2005-08-18
DK1497308T3 (da) 2007-01-29
EP1497308A1 (de) 2005-01-19
JP4490116B2 (ja) 2010-06-23
EP1497308B1 (de) 2006-09-20
US7148212B2 (en) 2006-12-12
BR0309357A (pt) 2005-02-22
CA2480004A1 (en) 2003-11-06
RU2315056C2 (ru) 2008-01-20
ZA200409401B (en) 2006-02-22
KR20040106380A (ko) 2004-12-17
CA2480004C (en) 2007-11-13
AU2003232491A1 (en) 2003-11-10
US20030216360A1 (en) 2003-11-20
WO2003091272A1 (de) 2003-11-06
ATE340186T1 (de) 2006-10-15
DE50305122D1 (de) 2006-11-02
PT1497308E (pt) 2007-01-31
ES2274258T3 (es) 2007-05-16

Similar Documents

Publication Publication Date Title
NO20045023L (no) Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer
NO20045073L (no) Fremgangsmate for fremstilling av krystaller, derved oppnaelige krystaller og deres anvendelse i farmasoytiske formuleringer
WO2003002196A3 (en) Multi-site ventricular pacing system measuring qrs duration
WO2001023390A3 (de) Azepinoindol-derivate, deren herstellung und anwendung
CA2369070A1 (en) 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
NZ579082A (en) Stable suspensions of micronised particles of a solid organic compound which is free of surfactants, thickeners, poly-electrolytes or block copolymers
CA2192731A1 (en) Monohydrates of aminobenzenesulfonic acid derivatives and method for preparing thereof
EP0073340A3 (en) Titanium dioxide pigment having improved photostability and process for producing same
AU4025689A (en) Method of using plant nucleoside derivatives for treatment of viral infections
DE69911197D1 (de) Herstellungsverfahren von kupferphthalocyanin in der beta modifikation
CA2482021A1 (en) Removal of adenine during a process of pathogen reducing blood and blood components
ATE496868T1 (de) Verfahren zur herstellung von siliciumdioxid aus olivin
NO20045071L (no) Fremgangsmate for fremstilling av krystaller ut i fra aktive legemiddelvirkestoffer, krystaller oppnadd derav og deres anvendelse i farmasoytiske formuleringer
Kapoor et al. Orotidine-5′-phosphate pyrophosphorylase of wheat embryos
CA2316739A1 (en) Preparation of cells for production of biologicals
YU107779A (en) Process for preparing derivatives of benzoylphenoxyalkanoic acid, which normalize the blood lipide level
JPH07114570B2 (ja) コーティング種子及びその製造方法
CN103755758A (zh) 一种制霉菌素的制备方法
DE59309480D1 (de) Verfahren zur herstellung einer physikalisch stabilen, kristallinen gamma-modifikation von para-aminobenzolsulfonamid
IE791438L (en) Oxadiazolotriazines
JPS537519A (en) Concentrating method for titanium component
JPH0347071A (ja) カンゾン根茎細胞のグリチルリチン高生産株取得方法
JPS56137895A (en) Direct saccharification of milo
Devyatkina et al. Use of Organic Complexformers During the Etching of Titanium
CA2617000A1 (en) Methods for preparing nevirapine hemihydrate and an aqueous suspension thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application